159 related articles for article (PubMed ID: 9888257)
1. Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.
Duarte J; Lugnier C; Torres AI; Pérez-Vizcaino F; Zarzuelo A; Tamargo J
Gen Pharmacol; 1999 Jan; 32(1):71-4. PubMed ID: 9888257
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
3. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
Pauvert O; Lugnier C; Keravis T; Marthan R; Rousseau E; Savineau JP
Br J Pharmacol; 2003 Jun; 139(3):513-22. PubMed ID: 12788811
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
Stehlik J; Movsesian MA
Expert Opin Investig Drugs; 2006 Jul; 15(7):733-42. PubMed ID: 16787138
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
6. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
O'Donnell JM; Frith S
Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-independent and endothelium-dependent vasorelaxation by a dichloromethane fraction from Anogeissus Leiocarpus (DC) Guill. Et Perr. (Combretaceae): possible involvement of cyclic nucleotide phosphodiesterase inhibition.
Belemnaba L; Ouédraogo S; Auger C; Chataigneau T; Traore A; Guissou IP; Lugnier C; Schini-Kerth VB; Bucher B
Afr J Tradit Complement Altern Med; 2013; 10(2):173-9. PubMed ID: 24146440
[TBL] [Abstract][Full Text] [Related]
8. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
9. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
Raeburn D; Advenier C
Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.
Ashikaga T; Strada SJ; Thompson WJ
Biochem Pharmacol; 1997 Nov; 54(10):1071-9. PubMed ID: 9464449
[TBL] [Abstract][Full Text] [Related]
11. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
Rybalkin SD; Bornfeldt KE
Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
[No Abstract] [Full Text] [Related]
12. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
13. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
14. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
15. The isoenzyme selectivity of AH 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity.
Elliott KR; Berry JL; Bate AJ; Foster RW; Small RC
J Enzyme Inhib; 1991; 4(3):245-51. PubMed ID: 1645399
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins.
Nichols MR; Morimoto BH
Mol Pharmacol; 2000 Apr; 57(4):738-45. PubMed ID: 10727520
[TBL] [Abstract][Full Text] [Related]
17. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
Némoz G; Prigent AF; Picq M; Pacheco H
Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
[No Abstract] [Full Text] [Related]
20. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
